Pliant Therapeutics, Inc.

NasdaqGS:PLRX Rapporto sulle azioni

Cap. di mercato: US$923.6m

Pliant Therapeutics Crescita futura

Future criteri di controllo 2/6

Si prevede che gli utili di Pliant Therapeutics diminuiranno a 3.2% all'anno, mentre si prevede che i suoi ricavi annuali cresceranno a 75.8% all'anno. Si prevede che l'EPS crescerà di 5.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà -156.1% in 3 anni.

Informazioni chiave

-3.2%

Tasso di crescita degli utili

5.5%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili23.6%
Tasso di crescita dei ricavi75.8%
Rendimento futuro del capitale proprio-156.1%
Copertura analitica

Good

Ultimo aggiornamento08 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?

Sep 13
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?

Pliant Therapeutics: Good Data, But Will Need Watching

Sep 11

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07
Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Feb 27
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Jul 21
Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Mar 13
Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Sep 10
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Pliant Therapeutics: Wait For A Better Price To Get In

Aug 20

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Aug 08

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28
Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Pliant's PLN-74809 gets FDA fast track status for liver disease

Jul 21

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Jul 11

Pliant: Major Catalyst Expected Beginning Of 2023

Jun 03

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22
We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29
Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07
We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

May 17
Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 13
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Mar 22
Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:PLRX - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20264-295-253-2308
12/31/20257-267-216-20910
12/31/20242-221-172-18110
6/30/2024N/A-185-140-137N/A
3/31/20240-171-119-116N/A
12/31/20232-161-117-116N/A
9/30/20234-155-124-122N/A
6/30/20235-144-106-105N/A
3/31/202310-133-106-104N/A
12/31/202210-123-96-95N/A
9/30/202210-113-85-83N/A
6/30/202210-109-89-87N/A
3/31/20227-103-85-82N/A
12/31/20218-97-77-75N/A
9/30/202110-92-74-72N/A
6/30/202113-81-67-65N/A
3/31/202115-75-40-38N/A
12/31/202042-42-39-37N/A
9/30/202094181516N/A
6/30/202090191617N/A
3/31/20208620-6-5N/A
12/31/201957-7-4-3N/A
3/31/2019N/A-43-33-32N/A
12/31/2018N/A-35-31-28N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che PLRX rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che PLRX rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che PLRX rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di PLRX ( 75.8% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di PLRX ( 75.8% all'anno) crescerà più rapidamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Si prevede che PLRX non sarà più redditizia tra 3 anni.


Scoprire le aziende in crescita